Sangamo Receives Fast Track Designation From The FDA For SB-318 And SB-913 In Vivo Genome Editing Product Candidates For The Treatment Of MPS I And MPS II - BioLegacy Research

Sangamo Receives Fast Track Designation From The FDA For SB-318 And SB-913 In Vivo Genome Editing Product Candidates For The Treatment Of MPS I And MPS II

Post author:Sam
Post published:July 13, 2017
Post category:BioPharma

Life Sciences Jobs …
Source: BioSpace